Post-COVID-19 syndrome
© 2023 Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine..
In the aftermath of acute infection with the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), a large number of symptoms persist or appear, constituting a real syndrome called "long COVID-19" or "post-COVID- 19" or "post-acute COVID-19 syndrome". Its incidence is very high, half of patients showing at least one symptom at 4-6 months after Coronarovirus infectious disease 2019 (COVID-19). They can affect many organs. The most common symptom is persistent fatigue, similar to that seen after other viral infections. Radiological pulmonary sequelae are relatively rare and not extensive. On the other hand, functional respiratory symptoms, primarily dyspnoea, are much more frequent. Dysfunctional breathing is a significant cause of dyspnoea. Cognitive disorders and psychological symptoms are also very common, with anxiety, depression and post-traumatic stress symptoms being widely described. On the other hand, cardiac, endocrine, cutaneous, digestive or renal sequelae are rarer. The symptoms generally improve after several months, even if their prevalence at two years remains significant. Most of the symptoms are favored by the severity of the initial illness, and the psychic symptoms by the female sex. The pathophysiology of most symptoms is poorly understood. The influence of the treatments used in the acute phase is also important. Vaccination, on the other hand, seems to reduce their incidence. The sheer number of affected patients makes long-term COVID-19 syndrome a public health challenge.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:207 |
|---|---|
| Enthalten in: |
Bulletin de l'Academie nationale de medecine - 207(2023), 6 vom: 02. Juni, Seite 812-820 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Syndrome post-COVID-19 |
|---|
| Beteiligte Personen: |
Montani, David [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anxiety |
|---|
| Anmerkungen: |
Date Revised 12.06.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.banm.2023.01.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357942078 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357942078 | ||
| 003 | DE-627 | ||
| 005 | 20231226073702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.banm.2023.01.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM357942078 | ||
| 035 | |a (NLM)37292432 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Montani, David |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Post-COVID-19 syndrome |
| 246 | 3 | 3 | |a Syndrome post-COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. | ||
| 520 | |a In the aftermath of acute infection with the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), a large number of symptoms persist or appear, constituting a real syndrome called "long COVID-19" or "post-COVID- 19" or "post-acute COVID-19 syndrome". Its incidence is very high, half of patients showing at least one symptom at 4-6 months after Coronarovirus infectious disease 2019 (COVID-19). They can affect many organs. The most common symptom is persistent fatigue, similar to that seen after other viral infections. Radiological pulmonary sequelae are relatively rare and not extensive. On the other hand, functional respiratory symptoms, primarily dyspnoea, are much more frequent. Dysfunctional breathing is a significant cause of dyspnoea. Cognitive disorders and psychological symptoms are also very common, with anxiety, depression and post-traumatic stress symptoms being widely described. On the other hand, cardiac, endocrine, cutaneous, digestive or renal sequelae are rarer. The symptoms generally improve after several months, even if their prevalence at two years remains significant. Most of the symptoms are favored by the severity of the initial illness, and the psychic symptoms by the female sex. The pathophysiology of most symptoms is poorly understood. The influence of the treatments used in the acute phase is also important. Vaccination, on the other hand, seems to reduce their incidence. The sheer number of affected patients makes long-term COVID-19 syndrome a public health challenge | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Anxiety | |
| 650 | 4 | |a Coronavirus infections | |
| 650 | 4 | |a Depression | |
| 650 | 4 | |a Dyspnea | |
| 650 | 4 | |a Long-term adverse effects | |
| 650 | 4 | |a Pulmonary fibrosis | |
| 650 | 4 | |a SARS virus | |
| 700 | 1 | |a Savale, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Noel, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Meyrignac, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Colle, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Gasnier, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Corruble, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Beurnier, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Jutant, Etienne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Tai |e verfasserin |4 aut | |
| 700 | 1 | |a Lecoq, Anne-Lise |e verfasserin |4 aut | |
| 700 | 1 | |a Papon, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Figuereido, Samy |e verfasserin |4 aut | |
| 700 | 1 | |a Harrois, Anatole |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Monnet, Xavier |e verfasserin |4 aut | |
| 700 | 0 | |a pour le Groupe d’étude Comebac |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bulletin de l'Academie nationale de medecine |d 1947 |g 207(2023), 6 vom: 02. Juni, Seite 812-820 |w (DE-627)NLM000463779 |x 0001-4079 |7 nnns |
| 773 | 1 | 8 | |g volume:207 |g year:2023 |g number:6 |g day:02 |g month:06 |g pages:812-820 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.banm.2023.01.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 207 |j 2023 |e 6 |b 02 |c 06 |h 812-820 | ||